Bliss GVS Pharma arm clears USFDA inspection of Ambernath facility

"The successful audit outcome from USFDA is a reflection of the steady progress that we are making into the mature pharma markets," Bliss GVS Pharma VP-Strategy & Business Development Gagan Harsh Sharma said.

New Delhi: Drug firm Bliss GVS Pharma has said its subsidiary Kremoint Pharma has cleared inspection of its Ambernath facility in Maharashtra by the US health regulator. The inspection by the United States Food and Drug Administration (USFDA) was conducted from June 17-20, 2019, Bliss GVS Pharma said in a statement.

"The successful audit outcome from USFDA is a reflection of the steady progress that we are making into the mature pharma markets," Bliss GVS Pharma VP-Strategy & Business Development Gagan Harsh Sharma said.

Read Also: Chennai-based Shield Healthcare acquires Brio Bliss Life Science, Nutri Synapzz

This along with the completion of the company's OSD manufacturing unit located at Palghar (Maharashtra) will further boost its growth into newer geographies, he added.

Headquartered in Mumbai, Bliss GVS primarily develops, manufactures and markets products across various therapeutic categories including Anti-fungal, Contraceptive, Laxative, Anti-haemorrhoidal, Anti-spasmodic, Anti-malarial, Anti-biotic, Anti-microbial, Anti-inflammatory, Antipyretic, Analgesic and several others.

Read Also: Anuh Pharma successfully clears USFDA inspection